Pipeline Keenova eyes Xiaflex as first drug for plantar fibromatosis PharmaphorumKeenova is hoping that its Xiaflex drug can become the first approved therapy for plantar fibromatosis, a debilitating condition affecting the feet.Rare DiseaseRead full story pharminent July 9, 2026 (Last updated: July 9, 2026) Pharmaphorum Keenova is hoping that its Xiaflex drug can become the first approved therapy for plantar fibromatosis, a debilitating condition affecting the feet. Rare Disease Read full story Post navigation Previous: AstraZeneca, Ionis drug fails big heart disease study in major setbackNext: Roche scraps two Ionis-partnered Huntington’s drugs Related Stories Pipeline Chasing Dupixent, a biotech aims to make better antibody drugs for eczema pharminent August 11, 2026 Pipeline Epicrispr lands $90M to advance epigenetic editing drug for rare muscle disease pharminent August 11, 2026 Pipeline BioMarin axes asset from $270M Inozyme takeover, ending run in rare metabolic indication pharminent August 10, 2026
